Marta Soares, Luís Antunes, Patrícia Redondo, Marina Borges, Ruben Hermans, Dony Patel, Fiona Grimson, Robin Munro, Carlos Chaib, Laure Lacoin, Melinda Daumont, John R Penrod, John C O'Donnell, Maria José Bento, Francisco Rocha Gonçalves
{"title":"Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database.","authors":"Marta Soares, Luís Antunes, Patrícia Redondo, Marina Borges, Ruben Hermans, Dony Patel, Fiona Grimson, Robin Munro, Carlos Chaib, Laure Lacoin, Melinda Daumont, John R Penrod, John C O'Donnell, Maria José Bento, Francisco Rocha Gonçalves","doi":"10.2217/lmt-2020-0028","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This observational study evaluated treatment patterns and survival for patients with stage I-IIIA non-small-cell lung cancer (NSCLC).</p><p><strong>Materials & methods: </strong>Adults newly diagnosed with NSCLC in 2012-2016 at IPO-Porto hospital were included. Treatment data were available for patients diagnosed in 2015-2016.</p><p><strong>Results: </strong>495 patients were included (median age: 67 years). The most common treatments were surgery alone or with another therapy (stage I: 66%) and systemic anticancer therapy plus radiotherapy (stage II: 54%; stage IIIA: 59%). One-year OS (95% CI) for patients with stage I, II and IIIA NSCLC (diagnosed 2012-2016) were 92% (88-96), 71% (62-82) and 69% (63-75), respectively; one-year OS (95% CI) for treated patients with stage I-II or stage IIIA NSCLC (diagnosed 2015-2016) were 89% (81-97) and 86% (75-98) for non-squamous cell and 76% (60-95) and 49% (34-70) for squamous cell NSCLC.</p><p><strong>Conclusion: </strong>Treatment advances are strongly needed for stage I-IIIA NSCLC, especially for patients with squamous cell histology.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"10 2","pages":"LMT46"},"PeriodicalIF":0.7000,"publicationDate":"2021-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/f5/lmt-10-46.PMC8162184.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2020-0028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 1
Abstract
Aim: This observational study evaluated treatment patterns and survival for patients with stage I-IIIA non-small-cell lung cancer (NSCLC).
Materials & methods: Adults newly diagnosed with NSCLC in 2012-2016 at IPO-Porto hospital were included. Treatment data were available for patients diagnosed in 2015-2016.
Results: 495 patients were included (median age: 67 years). The most common treatments were surgery alone or with another therapy (stage I: 66%) and systemic anticancer therapy plus radiotherapy (stage II: 54%; stage IIIA: 59%). One-year OS (95% CI) for patients with stage I, II and IIIA NSCLC (diagnosed 2012-2016) were 92% (88-96), 71% (62-82) and 69% (63-75), respectively; one-year OS (95% CI) for treated patients with stage I-II or stage IIIA NSCLC (diagnosed 2015-2016) were 89% (81-97) and 86% (75-98) for non-squamous cell and 76% (60-95) and 49% (34-70) for squamous cell NSCLC.
Conclusion: Treatment advances are strongly needed for stage I-IIIA NSCLC, especially for patients with squamous cell histology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
